Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

Objective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment. Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infan...

Full description

Saved in:
Bibliographic Details
Main Authors: Qinrui Hu, Yujing Bai, Xiaoli Chen, Lvzhen Huang, Yi Chen, Xiaoxin Li
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2017/5078565
Tags: Add Tag
No Tags, Be the first to tag this record!